© Drug Hunter Inc. 2018-2023
Home > AG-881
allosteric mutant IDH1/2 dual inhibitor
oral, brain penetrant, completed Ph. I in HV
from SBDD of prior mIDH inhibitor
ACS Med. Chem. Lett., 2020, 11, 101-107
Agios Pharmaceuticals, Cambridge, MA
AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year